These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 22228635)

  • 1. Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer.
    Sun W; Zaboli D; Wang H; Liu Y; Arnaoutakis D; Khan T; Khan Z; Koch WM; Califano JA
    Clin Cancer Res; 2012 Feb; 18(4):1082-91. PubMed ID: 22228635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of promoter hypermethylation pattern in salivary rinses collected with and without an exfoliating brush from patients with HNSCC.
    Sun W; Zaboli D; Liu Y; Arnaoutakis D; Khan T; Wang H; Koch W; Khan Z; Califano JA
    PLoS One; 2012; 7(3):e33642. PubMed ID: 22438973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of TIMP3 hypermethylation in post-treatment salivary rinse from head and neck squamous cell carcinoma patients.
    Rettori MM; de Carvalho AC; Bomfim Longo AL; de Oliveira CZ; Kowalski LP; Carvalho AL; Vettore AL
    Carcinogenesis; 2013 Jan; 34(1):20-7. PubMed ID: 23042095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
    De Schutter H; Geeraerts H; Verbeken E; Nuyts S
    Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of promoter hypermethylation in salivary rinses as a biomarker for head and neck squamous cell carcinoma surveillance.
    Carvalho AL; Henrique R; Jeronimo C; Nayak CS; Reddy AN; Hoque MO; Chang S; Brait M; Jiang WW; Kim MM; Claybourne Q; Goldenberg D; Khan Z; Khan T; Westra WH; Sidransky D; Koch W; Califano JA
    Clin Cancer Res; 2011 Jul; 17(14):4782-9. PubMed ID: 21628494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of methylation markers for diagnosis of oral cavity cancer.
    Arantes LM; de Carvalho AC; Melendez ME; Centrone CC; Góis-Filho JF; Toporcov TN; Caly DN; Tajara EH; Goloni-Bertollo EM; Carvalho AL;
    Eur J Cancer; 2015 Mar; 51(5):632-41. PubMed ID: 25686481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TIMP3 and CCNA1 hypermethylation in HNSCC is associated with an increased incidence of second primary tumors.
    Rettori MM; de Carvalho AC; Longo AL; de Oliveira CZ; Kowalski LP; Carvalho AL; Vettore AL
    J Transl Med; 2013 Dec; 11():316. PubMed ID: 24359512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the methylation profile of exfoliated cell samples from patients with head and neck squamous cell carcinoma.
    Longo AL; Rettori MM; de Carvalho AC; Kowalski LP; Carvalho AL; Vettore AL
    Head Neck; 2014 May; 36(5):631-7. PubMed ID: 23595968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma.
    Nayak CS; Carvalho AL; Jeronimo C; Henrique R; Kim MM; Hoque MO; Chang S; Jiang WW; Koch W; Westra W; Sidransky D; Califano J
    Laryngoscope; 2007 Aug; 117(8):1376-80. PubMed ID: 17592394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant promoter methylation can be useful as a marker of recurrent disease in patients with cervical intraepithelial neoplasia grade III.
    Terra AP; Murta EF; Maluf PJ; Caballero OL; Brait M; Adad SJ
    Tumori; 2007; 93(6):572-9. PubMed ID: 18338492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients.
    Buckingham L; Penfield Faber L; Kim A; Liptay M; Barger C; Basu S; Fidler M; Walters K; Bonomi P; Coon J
    Int J Cancer; 2010 Apr; 126(7):1630-9. PubMed ID: 19795445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DAPK promoter hypermethylation in tissues and body fluids of oral precancer patients.
    Liu Y; Zhou ZT; He QB; Jiang WW
    Med Oncol; 2012 Jun; 29(2):729-33. PubMed ID: 21516484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma.
    Krajnović M; Radojković M; Davidović R; Dimitrijević B; Krtolica K
    Med Oncol; 2013 Mar; 30(1):441. PubMed ID: 23275143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.
    Koutsimpelas D; Pongsapich W; Heinrich U; Mann S; Mann WJ; Brieger J
    Oncol Rep; 2012 Apr; 27(4):1135-41. PubMed ID: 22246327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of tumor-related genes hypermethylation detected in cancer-free surgical margins of oral squamous cell carcinomas.
    Supic G; Kozomara R; Jovic N; Zeljic K; Magic Z
    Oral Oncol; 2011 Aug; 47(8):702-8. PubMed ID: 21697000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA content and methylation of p16, DAPK and RASSF1A gene in tumour and distant, normal mucosal tissue of head and neck squamous cell carcinoma patients.
    Laytragoon-Lewin N; Chen F; Castro J; Elmberger G; Rutqvist LE; Lewin F; Turesson I; Lundgren J
    Anticancer Res; 2010 Nov; 30(11):4643-8. PubMed ID: 21115918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p16(INK4A) promoter hypermethylation is associated with invasiveness and prognosis of oral squamous cell carcinoma in an age-dependent manner.
    Su PF; Huang WL; Wu HT; Wu CH; Liu TY; Kao SY
    Oral Oncol; 2010 Oct; 46(10):734-9. PubMed ID: 20729138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylation status of nine tumor suppressor genes in multiple myeloma.
    Braggio E; Maiolino A; Gouveia ME; Magalhães R; Souto Filho JT; Garnica M; Nucci M; Renault IZ
    Int J Hematol; 2010 Jan; 91(1):87-96. PubMed ID: 20037750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant promoter methylation in pleural fluid DNA for diagnosis of malignant pleural effusion.
    Katayama H; Hiraki A; Aoe K; Fujiwara K; Matsuo K; Maeda T; Murakami T; Toyooka S; Sugi K; Ueoka H; Tanimoto M
    Int J Cancer; 2007 May; 120(10):2191-5. PubMed ID: 17285579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study of aberrant methylation of TSG in saliva in case of upper-aerodigestive-tract cancer].
    Righini CA; de Fraipont F; Timsit JF; Dassonville O; Milano G; Moro-Sibilot D
    Rev Stomatol Chir Maxillofac; 2008 Sep; 109(4):226-32. PubMed ID: 18760810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.